Does the media favor AMGN or REGN?

In the previous week, Amgen had 4 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 67 mentions for Amgen and 63 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.19 beat Regeneron Pharmaceuticals' score of 0.72 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 50 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 32 Very Positive mention(s) 3 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer REGN or GILD?

In the previous week, Gilead Sciences had 28 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 91 mentions for Gilead Sciences and 63 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.23 beat Regeneron Pharmaceuticals' score of 0.72 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 32 Very Positive mention(s) 3 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Gilead Sciences 66 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor REGN or MRNA?

In the previous week, Moderna had 18 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 81 mentions for Moderna and 63 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.72 beat Moderna's score of 0.59 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 32 Very Positive mention(s) 3 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Moderna 38 Very Positive mention(s) 8 Positive mention(s) 9 Neutral mention(s) 13 Negative mention(s) 9 Very Negative mention(s) Positive

Does the media refer more to NTLA or REGN?

In the previous week, Regeneron Pharmaceuticals had 60 more articles in the media than Intellia Therapeutics. MarketBeat recorded 63 mentions for Regeneron Pharmaceuticals and 3 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.72 beat Intellia Therapeutics' score of 0.47 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 32 Very Positive mention(s) 3 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to REGN or VIR?

In the previous week, Regeneron Pharmaceuticals had 61 more articles in the media than Vir Biotechnology. MarketBeat recorded 63 mentions for Regeneron Pharmaceuticals and 2 mentions for Vir Biotechnology. Regeneron Pharmaceuticals' average media sentiment score of 0.72 beat Vir Biotechnology's score of 0.10 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 32 Very Positive mention(s) 3 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Vir Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Regeneron Pharmaceuticals (REGN) Competitors

$826.64 -14.20 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$830.43 +3.79 (+0.46%)

As of 06:40 PM Eastern

Compare

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

Should you buy Regeneron Pharmaceuticals stock or one of its competitors? Regeneron Pharmaceuticals's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Regeneron Pharmaceuticals compare to Amgen?

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Amgen had 4 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 67 mentions for Amgen and 63 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.19 beat Regeneron Pharmaceuticals' score of 0.72 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	50 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	32 Very Positive mention(s)	3 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

Amgen presently has a consensus target price of $380.43, suggesting a potential downside of 12.29%. Regeneron Pharmaceuticals has a consensus target price of $801.70, suggesting a potential downside of 3.02%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.39
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Amgen pays out 62.6% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$38.10B	6.16	$7.71B	$16.09	26.96
Regeneron Pharmaceuticals	$14.34B	5.93	$4.50B	$40.46	20.43

Summary

Amgen beats Regeneron Pharmaceuticals on 12 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Gilead Sciences had 28 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 91 mentions for Gilead Sciences and 63 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.23 beat Regeneron Pharmaceuticals' score of 0.72 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	32 Very Positive mention(s)	3 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Gilead Sciences	66 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.93	$4.50B	$40.46	20.43
Gilead Sciences	$30.46B	5.84	$8.51B	-$2.67	N/A

Regeneron Pharmaceuticals has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Gilead Sciences' net margin of -10.64%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Gilead Sciences	-10.64%	-2.11%	-0.75%

Regeneron Pharmaceuticals presently has a consensus price target of $801.70, indicating a potential downside of 3.02%. Gilead Sciences has a consensus price target of $158.04, indicating a potential upside of 10.18%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.83

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.3%. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 12 of the 19 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Moderna?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, Moderna had 18 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 81 mentions for Moderna and 63 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.72 beat Moderna's score of 0.59 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	32 Very Positive mention(s)	3 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Moderna	38 Very Positive mention(s)	8 Positive mention(s)	9 Neutral mention(s)	13 Negative mention(s)	9 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Regeneron Pharmaceuticals currently has a consensus target price of $801.70, indicating a potential downside of 3.02%. Moderna has a consensus target price of $66.25, indicating a potential downside of 50.31%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Moderna's net margin of -141.43%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Moderna	-141.43%	-28.30%	-19.39%

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.93	$4.50B	$40.46	20.43
Moderna	$1.94B	27.38	-$2.82B	-$7.99	N/A

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Regeneron Pharmaceuticals had 60 more articles in the media than Intellia Therapeutics. MarketBeat recorded 63 mentions for Regeneron Pharmaceuticals and 3 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.72 beat Intellia Therapeutics' score of 0.47 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	32 Very Positive mention(s)	3 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Intellia Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.76	-$412.69M	-$3.36	N/A
Regeneron Pharmaceuticals	$14.34B	5.93	$4.50B	$40.46	20.43

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Intellia Therapeutics' net margin of -672.16%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Intellia Therapeutics currently has a consensus price target of $21.15, suggesting a potential upside of 70.03%. Regeneron Pharmaceuticals has a consensus price target of $801.70, suggesting a potential downside of 3.02%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

Regeneron Pharmaceuticals beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals presently has a consensus target price of $801.70, suggesting a potential downside of 3.02%. Vir Biotechnology has a consensus target price of $20.63, suggesting a potential upside of 123.94%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Regeneron Pharmaceuticals had 61 more articles in the media than Vir Biotechnology. MarketBeat recorded 63 mentions for Regeneron Pharmaceuticals and 2 mentions for Vir Biotechnology. Regeneron Pharmaceuticals' average media sentiment score of 0.72 beat Vir Biotechnology's score of 0.10 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	32 Very Positive mention(s)	3 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Vir Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Vir Biotechnology's net margin of -638.88%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.93	$4.50B	$40.46	20.43
Vir Biotechnology	$68.56M	22.73	-$437.99M	-$1.86	N/A

Summary

Regeneron Pharmaceuticals beats Vir Biotechnology on 12 of the 17 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REGN vs. The Competition

Export

Metric	Regeneron Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$85.11B	$3.96B	$7.22B	$12.76B
Dividend Yield	0.46%	3.66%	2.55%	10.29%
P/E Ratio	20.43	11.59	269.18	24.05
Price / Sales	5.93	1,365.49	621.56	97.96
Price / Cash	19.30	102.56	78.23	52.73
Price / Book	2.68	17.08	13.06	6.16
Net Income	$4.50B	-$12.52M	$3.46B	$347.49M
7 Day Performance	2.56%	2.74%	1.43%	-0.64%
1 Month Performance	22.98%	6.15%	4.58%	2.12%
1 Year Performance	39.87%	60.36%	27.60%	20.16%

Regeneron Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REGN Regeneron Pharmaceuticals	3.9353 of 5 stars	$826.64 -1.7%	$801.70 -3.0%	+47.1%	$85.11B	$14.34B	20.43	15,410	Trending News Analyst Forecast
AMGN Amgen	3.835 of 5 stars	$416.18 +0.5%	$371.68 -10.7%	+49.7%	$225.00B	$36.75B	25.87	31,500	Trending News Analyst Forecast Options Volume
GILD Gilead Sciences	4.2113 of 5 stars	$135.87 +0.1%	$158.04 +16.3%	+25.1%	$168.47B	$29.44B	N/A	17,000	Trending News Insider Trade Analyst Revision
MRNA Moderna	1.6727 of 5 stars	$63.67 +5.1%	$42.13 -33.8%	+524.8%	$25.42B	$2.21B	N/A	4,700	Trending News Analyst Upgrade Options Volume Gap Down
NTLA Intellia Therapeutics	2.8933 of 5 stars	$12.09 +0.6%	$20.85 +72.5%	+29.1%	$1.69B	$59.51M	N/A	600	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REGN) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Does the media favor AMGN or REGN?

Is AMGN or REGN more profitable?

Which has more risk and volatility, AMGN or REGN?

Do analysts rate AMGN or REGN?

Do institutionals & insiders hold more shares of AMGN or REGN?

Is AMGN or REGN a better dividend stock?

Which has stronger valuation & earnings, AMGN or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Does the media prefer REGN or GILD?

Which has better earnings & valuation, REGN or GILD?

Which has more volatility & risk, REGN or GILD?

Is REGN or GILD more profitable?

Do analysts recommend REGN or GILD?

Is REGN or GILD a better dividend stock?

Do institutionals and insiders believe in REGN or GILD?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Does the media favor REGN or MRNA?

Which has more risk and volatility, REGN or MRNA?

Do analysts rate REGN or MRNA?

Is REGN or MRNA more profitable?

Which has stronger earnings & valuation, REGN or MRNA?

Do insiders & institutionals believe in REGN or MRNA?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Do institutionals and insiders have more ownership in NTLA or REGN?

Does the media refer more to NTLA or REGN?

Which has more volatility & risk, NTLA or REGN?

Which has higher valuation and earnings, NTLA or REGN?

Is NTLA or REGN more profitable?

Do analysts prefer NTLA or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Do insiders and institutionals hold more shares of REGN or VIR?

Do analysts rate REGN or VIR?

Does the media refer more to REGN or VIR?

Which has more risk & volatility, REGN or VIR?

Is REGN or VIR more profitable?

Which has better earnings & valuation, REGN or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools